• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 4:49:20 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TGTX alert in real time by email
    SC 13G/A 1 tm216120d6_sc13ga.htm SC 13G/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

      

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 4)*

     

    TG THERAPEUTICS, INC. 

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    88322Q108

    (CUSIP Number)

     

    January 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 88322Q108   13G

     

      1.

    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only).

     

    RA Capital Management, L.P.

         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨                         
        (b) ¨ 
       

      3. SEC Use Only
         
      4. Citizenship or Place of Organization                    Delaware

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With
    5. Sole Voting Power 0 shares
    6. Shared Voting Power 6,361,123 shares
    7. Sole Dispositive Power 0 shares
    8. Shared Dispositive Power 6,361,123 shares

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,361,123 shares

     

      10.

    Check if the Aggregate Amount in Row (9) Excludes                        ¨

     

    Certain Shares (See Instructions)

     

      11.

    Percent of Class Represented by Amount in Row (9)

    4.7%1

     

      12.

    Type of Reporting Person (See Instructions)

    IA, PN

     

     

    1 The percentage calculation assumes that there are currently 136,186,552 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 424B5 Prospectus as filed with the Securities and Exchange Commission (“SEC”) on December 16, 2020 and giving effect to an additional 948,000 shares issued and sold pursuant to the underwriters’ option.

     

     

     

     

    CUSIP No. 88322Q108   13G

     

      1.

    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only).

     

    Peter Kolchinsky

         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  ¨                      
           
      3. SEC Use Only
         
      4. Citizenship or Place of Organization                     United States

      5. Sole Voting Power 0 shares 
    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With
    6. Shared Voting Power 6,361,123 shares
    7. Sole Dispositive Power 0 shares
    8. Shared Dispositive Power 6,361,123 shares

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,361,123 shares

     

      10.

    Check if the Aggregate Amount in Row (9) Excludes                        ¨

     

    Certain Shares (See Instructions)

     

      11.

    Percent of Class Represented by Amount in Row (9)

    4.7%1

     

     
      12.

    Type of Reporting Person (See Instructions)

    HC, IN

     

     

     

     1 The percentage calculation assumes that there are currently 136,186,552 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 424B5 Prospectus as filed with the Securities and Exchange Commission (“SEC”) on December 16, 2020 and giving effect to an additional 948,000 shares issued and sold pursuant to the underwriters’ option.

     

     

     

     

    CUSIP No. 88322Q108   13G

     

      1.

    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only).

     

    Rajeev Shah

         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨                  
        (b)  ¨
           
      3. SEC Use Only
         
      4. Citizenship or Place of Organization         United States

      5.

    Sole Voting Power

    0 shares

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With
    6. Shared Voting Power 6,361,123 shares
    7. Sole Dispositive Power 0 shares
    8. Shared Dispositive Power 6,361,123 shares

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,361,123 shares

     

      10.

    Check if the Aggregate Amount in Row (9) Excludes                         ¨

     

    Certain Shares (See Instructions)

     

      11.

    Percent of Class Represented by Amount in Row (9)

    4.7%1

     

      12.

    Type of Reporting Person (See Instructions)

    HC, IN

     

     

     

    1 The percentage calculation assumes that there are currently 136,186,552 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 424B5 Prospectus as filed with the Securities and Exchange Commission (“SEC”) on December 16, 2020 and giving effect to an additional 948,000 shares issued and sold pursuant to the underwriters’ option.

     

     

     

     

    CUSIP No. 88322Q108   13G

     

      1.

    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only).

     

    RA Capital Healthcare Fund, L.P.

         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨                          
        (b)  ¨
           
      3. SEC Use Only
         
      4. Citizenship or Place of Organization                     Delaware

      5.

    Sole Voting Power  

    0 shares

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With
    6. Shared Voting Power 5,817,933 shares
    7. Sole Dispositive Power  0 shares
    8. Shared Dispositive Power  5,817,933 shares

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,817,933 shares

     

      10.

    Check if the Aggregate Amount in Row (9) Excludes                           ¨

     

    Certain Shares (See Instructions)

     

      11.

    Percent of Class Represented by Amount in Row (9)

    4.3%1

     

      12.

    Type of Reporting Person (See Instructions)

    PN

     

     

     

    1 The percentage calculation assumes that there are currently 136,186,552 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 424B5 Prospectus as filed with the Securities and Exchange Commission (“SEC”) on December 16, 2020 and giving effect to an additional 948,000 shares issued and sold pursuant to the underwriters’ option.

     

     

     

     

     

    CUSIP No. 88322Q108 13G

     

    Item 1.  

     

    (a)       Name of Issuer: TG Therapeutics, Inc. (the “Issuer”).

     

    (b)       Address of the Issuer’s Principal Executive Offices: 2 Gansevoort Street, 9th Floor, New York, NY 10014.

     

    Item 2.

     

    (a)       Name of Person Filing: This Amendment No. 4 to Schedule 13G amends and restates the Statement on Schedule 13G filed by RA Capital Management, L.P. (“RA Capital”), Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the “Fund”) (collectively, the “Reporting Persons”) on February 14, 2019 and amended on February 14, 2020, June 10, 2020 and February 10, 2021.

     

    The Common Stock reported herein includes 5,817,933 shares held by the Fund and 543,190 shares held in a separately managed account (the “Account”). RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and the Account and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund and the Account. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G Statement (the “Statement”) other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    (b)       Address of Principal Business Office: The principal business office of the Reporting Persons is c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, MA 02116.

     

    (c)        Citizenship: RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    (d)       Title and Class of Securities: Common stock (“Common Stock”)

     

    (e)       CUSIP Number: 88322Q108

     

     

     

     

    CUSIP No. 88322Q108 13G

     

     

      Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (e) RA Capital Management, L.P. is a registered investment adviser and is filing this statement in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (g) Peter Kolchinsky and Rajeev Shah are control persons and are filing this statement in accordance with §240.13d-1(b)(1)(ii)(G).

     

     

    Item 4.Ownership:

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount Beneficially Owned:

    See the response(s) to Item 9 on the attached cover page(s).

     

       
    (b)

    Percent of Class:

    See the response(s) to Item 11 on the attached cover page(s).

       
    (c) Number of shares as to which such person has:
      (i)

    sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

         
      (ii)

    shared power to vote or to direct the vote

    See the response(s) to Item 6 on the attached cover page(s).

         
      (iii)

    sole power to dispose or to direct the disposition of

    See the response(s) to Item 7 on the attached cover page(s).

         
      (iv)

    shared power to dispose or to direct the disposition of

    See the response(s) to Item 8 on the attached cover page(s).

       
       
       

     

     

     

     

    CUSIP No. 88322Q108 13G

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person:

     

    Not applicable.

     

    Item 7.                   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group:

     

    Not applicable.

     

    Item 9 Notice of Dissolution of Group:

     

    Not applicable.

     

    Item 10.Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 88322Q108 13G

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Date: February 10, 2021
       
      RA CAPITAL MANAGEMENT, L.P.
       
      By: /s/ Peter Kolchinsky
      Peter Kolchinsky
      Authorized Signatory
       
      PETER KOLCHINSKY
       
      /s/ Peter Kolchinsky
       
      RAJEEV SHAH
       
      /s/ Rajeev Shah
       
      RA CAPITAL HEALTHCARE FUND, L.P.
      By: RA Capital Healthcare GP, LLC
       
      By: /s/ Peter Kolchinsky
      Peter Kolchinsky
      Authorized Signatory
       

     

     

     

     

     

    CUSIP No. 88322Q108 13G

     

    AGREEMENT

     

    This Joint Filing Agreement, dated as of February 10, 2021, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

     

    Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock, par value $0.001 per share of TG Therapeutics, Inc. beneficially owned by them from time to time.

     

    Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

     

    This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    Executed and delivered as of the date first above written.

     

    RA CAPITAL MANAGEMENT, L.P.  
       
    By: /s/ Peter Kolchinsky  
      Name:Peter Kolchinsky  
      Title:Authorized Signatory  
       
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare GP, LLC  
       
    By:            /s/ Peter Kolchinsky  
      Name:Peter Kolchinsky  
      Title:Manager  

     

     

     

    Get the next $TGTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TGTX

    DatePrice TargetRatingAnalyst
    10/6/2025$60.00Buy
    H.C. Wainwright
    7/10/2025$37.00Neutral
    Goldman
    10/29/2024$50.00Buy
    TD Cowen
    8/2/2023$16.00 → $12.00Sell → Neutral
    Goldman
    6/26/2023$55.00 → $40.00Buy
    Jefferies
    5/20/2022$5.00Underperform
    BofA Securities
    2/23/2022$49.00 → $35.00Buy
    B. Riley Securities
    1/28/2022$70.00 → $68.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TGTX
    SEC Filings

    View All

    TG Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)

    1/13/26 4:27:48 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by TG Therapeutics Inc.

    SCHEDULE 13G - TG THERAPEUTICS, INC. (0001001316) (Subject)

    11/10/25 8:58:45 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by TG Therapeutics Inc.

    10-Q - TG THERAPEUTICS, INC. (0001001316) (Filer)

    11/5/25 4:31:23 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TGTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for UKONIQ

    Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

    2/9/21 12:05:59 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on TG Therapeutics with a new price target

    H.C. Wainwright resumed coverage of TG Therapeutics with a rating of Buy and set a new price target of $60.00

    10/6/25 8:31:23 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on TG Therapeutics with a new price target

    Goldman resumed coverage of TG Therapeutics with a rating of Neutral and set a new price target of $37.00

    7/10/25 9:01:31 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on TG Therapeutics with a new price target

    TD Cowen initiated coverage of TG Therapeutics with a rating of Buy and set a new price target of $50.00

    10/29/24 6:30:43 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TGTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $TGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We are pleased to share data at this year's ACTRIMS annual meeting, including updates from the ENABLE real world study evaluating patients with RMS on BRIUMVI. Our presentations reflect our continued focus on advancing the clinical understanding of

    2/6/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

    NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 5 – 7, 2026 in San Diego, California. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the upcoming presentations are outlined below. TG PRESENTATIONS:Poster Presentation Title: Real-World Infusion Experience with Ublituximab in ENABLE: the First Phase 4 Observational Study for Patients with Relapsing Multipl

    1/27/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones

    Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million, respectivelyFull Year 2026 target total global revenue of approximately $875-900 million, including BRIUMVI U.S. net product revenue of approximately $825-850 million NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics), today announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2025 (unaudited), as well as 2026 financial guidance and development milestones, during

    1/13/26 4:25:00 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Charney Laurence N gifted 43,197 shares, decreasing direct ownership by 19% to 179,690 units (SEC Form 4)

    4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

    1/29/26 5:24:42 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Weiss Michael S was granted 622,000 shares, increasing direct ownership by 7% to 9,778,086 units (SEC Form 4)

    4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

    1/9/26 5:16:39 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Power Sean A was granted 90,000 shares, increasing direct ownership by 13% to 798,111 units (SEC Form 4)

    4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

    1/9/26 5:15:33 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.

    SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

    11/14/24 7:45:34 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

    SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

    2/14/24 3:30:53 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

    SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

    1/25/24 11:29:01 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TGTX
    Financials

    Live finance-specific insights

    View All

    TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

    Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target to approximately $585 million Conference call to be held today, Monday, November 3, 2025, at 8:30 AM ET    NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2025, along with recent company developments, and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "We are pleased to

    11/3/25 7:00:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

    NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. A

    10/31/25 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

    Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million Conference call to be held today, Monday, August 4, 2025, at 8:30 AM ET    NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the second quarter of 2025, along with recent company developments, and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "We're incredibly proud of the continued momentum behind BRIUMVI, which

    8/4/25 7:00:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TGTX
    Leadership Updates

    Live Leadership Updates

    View All

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care